<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">A tissue- and cell-targeted long-acting four-in-one nanosuspension composed of lopinavir, RTV, TFV, and LVD administered as a single injection subcutaneously to four macaques was able to exhibit persistent drug levels in lymph node mononuclear cells and peripheral blood mononuclear cells for 5Â weeks and could be proposed for a long-acting treatment with the potential to target residual virus in tissues and improve patient adherence (McConnachie et al. 
 <xref ref-type="bibr" rid="CR144">2018</xref>).
</p>
